Showing results (1-10 of 365) with videos related to
Sort By:
Pageof 37
Oncoimmunology|July 4, 2012
Know thy enemy: Why are tumor-infiltrating regulatory T cells so deleterious?Andrea Facciabene, Stephen Santoro, George CoukosCancer Research|May 3, 2012
T-regulatory cells: key players in tumor immune escape and angiogenesisAndrea Facciabene, Gregory T Motz, George CoukosClinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2009
Endothelin B receptor, a new target in cancer immune therapyLana E Kandalaft, Andrea Facciabene, Ron J Buckanovich, et al.Gynecologic Oncology|December 5, 2009
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decadeLana E Kandalaft, Nathan Singh, John B Liao, et al.Journal of Translational Medicine|May 26, 2011
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapyIoannis Alagkiozidis, Andrea Facciabene, Marinos Tsiatas, et al.Nature Medicine|December 25, 2007
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapyRonald J Buckanovich, Andrea Facciabene, Sarah Kim, et al.Journal for Immunotherapy of Cancer|April 13, 2026
Gut-targeted strategies at the intersection of radiotherapy and immunotherapyAndrea Facciabene, Susannah G EllsworthThe Journal of Clinical Investigation|March 20, 2014
Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculatureJohn G Facciponte, Stefano Ugel, Francesco De Sanctis, et al.Cancer|May 28, 2009
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancerSarah F Adams, Douglas A Levine, Mark G Cadungog, et al.Nature|July 15, 2011
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cellsAndrea Facciabene, Xiaohui Peng, Ian S Hagemann, et al.Pageof 37